European CHMP recommends approval of pemigatinib (Pemazyre) for second-line treatment of advanced or metastatic cholangiocarcinoma

Pemigatinib is an oral inhibitor of fibroblast growth factor receptor (FGFR); isoforms 1 2 and 3. It is intended to be licensed as monotherapy for adults with a FGFR isoform 2 fusion that is relapsed/refractory after at least one line of systemic therapy.

Source:

European Medicines Agency